Intra-cellular Therapies Stock News

Received FDA approval for CAPLYTA ® (lumateperone) for the treatment of bipolar depression in adults.

Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0

Within the last quarter, Intra-Cellular Therapies (NASDAQ: ITCI ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 0 0 0 These 5 analysts have an average price target of $58.6 versus the current price of Intra-Cellular Therapies at $53.57, implying upside. Below is a summary of how these 5 analysts rated Intra-Cellular Therapies over the past 3 months. The greater the number of bullish ratings, the … Full story available on Benzinga.com

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, March 1, 2022, to provide a corporate update and discuss details of the Company''s financial results for the quarter and year ended December 31, 2021.

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ: ITCI ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $57.0 versus the current price of Intra-Cellular Therapies at $55.53, implying upside. Below is a summary of how these 4 analysts rated Intra-Cellular Therapies over the past 3 months. The greater the number of bullish ratings, the more positive analysts … Full story available on Benzinga.com

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Intra-Cellular Therapies Inc. (NASDAQ: ITCI ) traded today at a new 12-month high of $56.81. So far today approximately 471,000 shares have been exchanged, as compared to an average 30-day volume of 1.5 million shares. Over the past year, Intra-Cellular Therapies Inc. has traded in a range of $28.40 to $56.81 and is now at $56.02, 97% above that low. Potential upside of 0.9% exists for Intra-Cellular Therapies Inc., based on a current level of $56.02 and analysts’ average consensus price target of $56.52. Intra-Cellular Therapies Inc. is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule … Full story available on Benzinga.com

Upgrades According to Compass Point, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Buy. Comerica earned $1.66 in the fourth quarter, compared to $1.49 in the year-ago quarte

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne